ZNTL broke 80 again today and is displaying a strong monthly momentum chart. IBB regaining 160 hopefully will signal at least a moderate health care push that could push ZNTL into the 90s and beyond. Good luck traders!
Beyond Air has continued a strong uptrend since June. Recently its bin tapering and has shown a symmetrical triangle formation. A Brake out to the upside is likely to continue the uptrend. Watch for a move past the top of the triangle at 11.88 level for conformation and more possible upside. No resistance till 12.50 a high not seen since March 4, 2020
Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668. Merck & Co. was established as an American affiliate in 1891
Entry on the bullish break of the dynamic...
Good news and even better volume today. We should see this build a base around $10 - $12. Earnings on the 29th should be interesting.
VWAP rejected and momentum slowed down.
Long $IPA. There is no way big pharma doesn't like this play.
A company with over 10 years of consistent and constant growth, a wide coverage of products already on the market and... despite an excellent quarterly for a news or a trail .. boom .. It drops suddenly ?
In my opinion this is sheer market madness, the sites I use as a reference for fundamental analysis confirm to me what I say, the company always be more than...
Novavax COVID-19 vaccine more than 90% effective in U.S trial according to Reuters. Despite positive news (which we do not trade), we will share with you our current view on Novavax.
a) The price is inside a descending Wedge, and due to positive news, we are observing a bullish GAP, and we may see the price outside the Wedge pattern
b) The general strategy...
Bullish news on cancer research and a looming patent publish date ETA June 1st. Earnings suck but they're shedding debt notes maybe for a buyout? Heads up on breakouts (short sellers wet dream). Cups within cups within cups. Dunno, DYOR and not investment advice.
-The company said that it has reached into a multi-program research collaboration and license agreement with Genentech, a member of the Roche Group, to discover, develop and commercialize locally delivered respiratory and ophthalmology therapies that leverage Pieris’ proprietary Anticalin® technology.
-PIRS went on to explain that the collaboration will enable it...